These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 30720484)

  • 1. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management.
    Widschwendter CG; Hofer A
    Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
    Correll CU; Kane JM; Citrome LL
    J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia and new antipsychotics.
    Correll CU; Schenk EM
    Curr Opin Psychiatry; 2008 Mar; 21(2):151-6. PubMed ID: 18332662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Tardive Dyskinesia.
    Bashir HH; Jankovic J
    Neurol Clin; 2020 May; 38(2):379-396. PubMed ID: 32279716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Recommendations for Tardive Dyskinesia.
    Ricciardi L; Pringsheim T; Barnes TRE; Martino D; Gardner D; Remington G; Addington D; Morgante F; Poole N; Carson A; Edwards M
    Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN; Aggarwal S; Yonan C
    J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valbenazine for Tardive Dyskinesia.
    Freudenreich O; Remington G
    Clin Schizophr Relat Psychoses; 2017; 11(2):113-119. PubMed ID: 28742396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for the development of tardive dyskinesia.
    Solmi M; Pigato G; Kane JM; Correll CU
    J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
    Witter DP; Holbert RC; Suryadevara U
    Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
    Carbon M; Hsieh CH; Kane JM; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.
    Loughlin AM; Lin N; Abler V; Carroll B
    PLoS One; 2019; 14(6):e0216044. PubMed ID: 31163035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.